Welcome to our dedicated page for Compass Pathways news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways stock.
COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
Compass Pathways (Nasdaq: CMPS) announced that its management will participate in the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026. A fireside chat is scheduled for May 19 at 10:00am ET, with a live and 30-day replay webcast via the company’s investor site.
Compass Pathways (Nasdaq: CMPS) reported Q1 2026 results and regulatory milestones for COMP360 psilocybin therapy in treatment-resistant depression.
FDA granted a rolling NDA submission, with final filing targeted for Q4 2026. COMP360 also received a Commissioner’s National Priority Review Voucher, which may shorten review to 1–2 months after filing.
Q1 2026 research and development expenses were $26.5 million and general and administrative expenses were $16.4 million. Net income reached $91.2 million, mainly from a non-cash warrant fair value gain of $130.9 million. Cash and equivalents rose to $466 million, with debt at $50.5 million and cash runway expected to extend into 2028.
Compass Pathways (Nasdaq: CMPS) will release first quarter 2026 financial results and business updates on May 13, 2026. Management will host a conference call and live webcast on May 13, 2026 at 8:00 AM ET (1:00 PM UK). The webcast will be archived for 30 days.
Compass Pathways (Nasdaq: CMPS) granted inducement equity awards on May 1, 2026 to 13 newly hired non-executive employees under the 2026 Inducement Plan.
The awards include options covering an aggregate of 125,335 shares and RSUs/nominal cost options covering 59,625 shares, exercise price $9.01, vesting over up to four years, and were approved under Nasdaq Listing Rule 5635(c)(4).
Compass Pathways (Nasdaq: CMPS) announced the FDA granted a rolling NDA submission and review for COMP360 and that COMP360 received a Commissioner's National Priority Voucher (CNPV) for treatment‑resistant depression (TRD).
The CNPV offers enhanced FDA communications and a shortened 1–2 month review window after NDA filing. Compass cites positive results from two Phase 3 trials across >1,000 TRD participants and reports rapid onset (as soon as one day) and durability through six months for responders, with most treatment‑emergent adverse events mild/moderate and resolving within 24 hours.
Compass Pathways (NASDAQ: CMPS) announced a collaboration with Osmind to study how small-to-medium independent psychiatry clinics can prepare to deliver psychedelic treatments, including COMP360, if FDA approved. The partnership will assess operational, clinical, and infrastructure needs across Osmind’s network of over 1,000 clinics to inform scalable, real-world delivery pathways.
Compass Pathways (Nasdaq: CMPS) announced CEO Kabir Nath will join a panel titled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026 from 11:00–12:00 ET.
A live audio webcast will stream from the company’s Investors > Events page, and a replay will be available for 30 days after the event.
Compass Pathways (Nasdaq: CMPS) welcomed the White House Executive Order to accelerate psychedelic treatments for serious mental illness. Compass highlighted two positive phase 3 COMP360 trials in treatment-resistant depression (TRD) with >1,000 participants, rapid effects within one day and durability to six months.
The company is working on a rolling FDA submission for COMP360 in TRD and is starting a late-stage PTSD trial after IND clearance.
Compass Pathways (Nasdaq: CMPS) launched a U.S. grant program to fund creation of provider training for investigational COMP360 psilocybin treatment ahead of a potential commercial launch. Compass expects to award up to three grants. Applications open April 14–May 14, 2026 at training-grants.compasspathways.com.
The program targets established U.S. training organizations to build foundational psychedelic and COMP360-specific modules to support clinical readiness and consistent patient care if COMP360 is approved.
Compass Pathways (Nasdaq: CMPS) will attend the Needham Virtual Healthcare Conference on April 14, 2026 and participate in a fireside chat at 12:45 PM ET. A live audio webcast will be available on the company’s Investors "Events" page.
According to the company, a replay of the webcast will be accessible for 30 days following the event.